A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce ...

Bluebird concluded its treatment didn't cause the condition, but the revelation started a series of questions surrounding the safety of its DNA-altering treatments. Bluebird also faced pushback ...

Dr Anup Rawool, Consultant in Clinical and Cancer Genetics at Sahyadri Hospitals, Pune, discusses innovative therapies and ...

Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have ...

The researchers, in a study published Feb. 25 in Nature Immunology, found that a DNA transcription-regulating protein ... Similarly, some gene therapies, especially for blood disorders such as ...

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study. The discovery could lead ...

U.S.-based companies are dragging down the major stock market indexes. But getting caught up in short-term market movements ...

Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle ... series of questions surrounding the safety of its DNA-altering treatments. Bluebird also faced pushback ...

On December 8, 2023, the United States’ Food and Drug Administration (FDA) approved of a gene therapy treatment for transfusion dependent beta-thalassemia ... or add DNA sequences at precise ...